Our Team
Founders
Led by a world class management and advisory team with complementary expertise in the pathobiology of autoimmune diseases, computational biology, medicinal chemistry, drug development, clinical trial design, and regulatory strategy. We believe the solution to complex diseases requires a system based approach.
Senior Management
Athos Therapeutics is led by a world-class management team with a strong pharma, business and academic record in therapeutic drug development.
Dimitrios Iliopoulos, PhD, MBA
President & CEO
Allan J. Pantuck, MD, MS
Chief Medical Officer
Jodi Pantuck, BBA
Chief of Staff and Operations
Keith B. Hoffman, PhD
Iordanis Karagiannidis, PhD
Chief Scientific Officer
David G. Ho, PhD
VP, Medicinal Chemistry & Intellectual Property
Phithi Nguyen
VP, Analytical Chemistry & Quality Assurance
Dimitra Chalkia, PhD
VP, Computational Biology
June Guo, PhD
VP, Artificial Intelligence & Machine Learning
Scientific Advisory Board
The Athos Therapeutics Scientific Advisory Board (SAB) is comprised of an unrivaled, international group of world-renowned leaders who are experts in the fields of immunology, inflammatory bowel diseases, drug discovery and development. They are providing strategic and scientific advice to the Athos management team in order to guide the development of our innovative therapeutic programs for autoimmune diseases.
Claudio Fiocchi, MD
Cleveland Clinic
Cleveland, USA
David Rubin, MD
University of Chicago
Chicago, USA
Jean-Frederick Colombel, MD
Icahn School of Medicine at Mount Sinai
New York, USA
Severine Vermeire, MD, PhD
Catholic University of Leuven
Leuven, Belgium
Michael Jung, MD
UCLA
Los Angeles, USA
Iris Dotan, MD
RABIN MEDICAL CENTER
PETAH TIKVA, ISRAEL
Silvio Danese, MD, PhD
Humanitas University
Milan, Italy
Julian Panes, MD
Hospital Clinic
Barcelona, Spain
Departments
Computational Biology & Artificial Intelligence
Infrastructure to analyze complex molecular and clinical data derived from samples from patients with autoimmune diseases, using an artificial intelligence framework
Riccardo Calandrelli
Principal Scientist II
Dimitra Chalkia, PhD
VP, Computational Biology
June Guo, PhD
VP, Artificial Intelligence & Machine Learning
Colin Robertson
Director, Product Design
Tung Hoang
Director, Software Architecture
Analytical Chemistry
Perform quality control analysis, including absorption, delivery and solubility of the drug compounds developed by the medicinal chemistry team
Phithi Nguyen
VP, Analytical Chemistry & Quality Assurance
Nalin Singh, PhD
Senior Research Scientist, Analytical Chemistry
Medicinal Chemistry
Infrastructure to design and synthesize new chemical drug compounds against gene targets identified by our computational platform
David G. Ho, PhD
VP, Medicinal Chemistry & Intellectual Property
Yonglong Xiao, PhD
Senior Scientist II, Medicinal Chemistry
Operations
Supporting day to day business operations, including finance, human resources and lab management.
Errin Gilliland
Executive Administrative Assistant
Jodi Pantuck
CHIEF OF STAFF & OPERATIONS
Jonathan Abdala
Assistant Director of Operations
Regulatory Affairs
Regulatory strategy planning for novel drug development (quality, nonclinical, clinical), support regulatory submissions, and interact with US FDA & global regulatory agencies to conduct clinical studies to establish safety & efficacy of novel drugs.
Priti Prasad, PhD, MS
Senior Director of Regulatory Affairs
Translational Biology
Evaluate the safety and efficacy profile of novel drug compounds in cellular and animal models of autoimmune diseases and cancer.
Iordanis Karagiannidis, PhD
CHIEF SCIENTIFIC OFFICER
Malvina Tsamouri, DVM, PhD, MSc
Assistant Director of Translational Medicine
George Dialynas, PhD
Senior Director, Translational Biology
Ellen O' Connor, PhD
Senior Scientist I, Translational Biology